(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S416000, C514S417000, C548S451000, C548S472000, C564S080000

Reexamination Certificate

active

07427638

ABSTRACT:
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3322755 (1967-05-01), Roch et al.
patent: 3920636 (1975-11-01), Takahashi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4047404 (1977-09-01), Hayashi
patent: 4060615 (1977-11-01), Matier et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4162316 (1979-07-01), Nishimura et al.
patent: 4209623 (1980-06-01), Juby
patent: 4880810 (1989-11-01), Lowe, III
patent: 4885301 (1989-12-01), Coates
patent: 5147875 (1992-09-01), Coates et al.
patent: 5354571 (1994-10-01), Morikawa et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5488055 (1996-01-01), Kumar et al.
patent: 5608914 (1997-03-01), Keesler
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5710170 (1998-01-01), Guay et al.
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5798373 (1998-08-01), Warrellow
patent: 5801195 (1998-09-01), Muller et al.
patent: 5849770 (1998-12-01), Head et al.
patent: 5877200 (1999-03-01), Muller
patent: 5891896 (1999-04-01), Warrellow et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6069156 (2000-05-01), Oku et al.
patent: 6162830 (2000-12-01), Connor et al.
patent: 6166041 (2000-12-01), Cavalla et al.
patent: 6177471 (2001-01-01), Menander et al.
patent: 6204275 (2001-03-01), Friesen et al.
patent: 6218400 (2001-04-01), Daugan et al.
patent: 6300335 (2001-10-01), Campbell et al.
patent: 6316472 (2001-11-01), Frenette et al.
patent: 6333354 (2001-12-01), Schudt
patent: 0 347 146 (1989-06-01), None
patent: 0 349 239 (1989-06-01), None
patent: 0 351 058 (1989-06-01), None
patent: 0 352 960 (1989-07-01), None
patent: 0 395 328 (1990-04-01), None
patent: 0 428 268 (1990-10-01), None
patent: 0 463 756 (1991-06-01), None
patent: 0 526 004 (1992-07-01), None
patent: 0 607 439 (1992-09-01), None
patent: 0 722 937 (1996-01-01), None
patent: 0 722 943 (1996-01-01), None
patent: 0 722 944 (1996-01-01), None
patent: 2 063 249 (1980-09-01), None
patent: WO 93/07149 (1993-04-01), None
patent: WO 93/12095 (1993-06-01), None
patent: WO 94/01728 (1994-01-01), None
patent: WO 94/05661 (1994-03-01), None
patent: WO 94/29277 (1994-12-01), None
patent: WO 95/19978 (1995-07-01), None
patent: WO 96/32379 (1996-10-01), None
patent: WO 97/03070 (1997-01-01), None
patent: WO 97/03675 (1997-02-01), None
patent: WO 97/03985 (1997-02-01), None
patent: WO 97/24334 (1997-07-01), None
patent: WO 98/06722 (1998-02-01), None
patent: WO 98/08848 (1998-03-01), None
patent: WO 98/14448 (1998-04-01), None
patent: WO 98/16521 (1998-04-01), None
patent: WO 98/17668 (1998-04-01), None
patent: WO 98/23597 (1998-06-01), None
patent: WO 98/38168 (1998-09-01), None
patent: WO 99/06041 (1999-02-01), None
Craven et al., 1969, CAS: 71:117431.
Berge et al., Journal of Pharmaceutical Science, 1977, vol. 66, pp. 1-19.
Bundgaard et al. publication, 1985, Design of prodrug, pp. 1-4.
FDA's guidance for industry, 2000, pp. 1-20.
Dredge et al., 2003, “Angiogenesis inhibitors in cancer therapy,” Curr. Opin. Investig. Drugs 4(6):667-674.
Dredge et al., 2002, “Immunological effects of thalidomide and its chemical and functional analogs,”Crit. Rev. Immunol.22(5-6):425-437.
Dredge et al., 2002, “Recent developments in antiangiogenic therapy,”Expert Opin. Biol. Ther.2(8):953-966.
Gee et al., 2003, “Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition,”Cancer Res.63(23):8073-8078.
Marriott et al., 2001, “Immunotherapeutic and antitumour potential of thalidomide analogues,”Expert Opin. Biol. Ther.1(4):1-8.
Marriott et al., 2002, “Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells,”Clin. Exp. Immunol.130(1):75-84.
Molostvov et al., 2004, “The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures,”Br. J. Haematol.124(3):366-375.
U.S. Appl. No. 60/454,155, filed Mar. 12, 2003, Muller, G. et al.
U.S. Appl. No. 60/454,149, filed Mar. 12, 2003, Muller, G. et al.
U.S. Appl. No. 60/438,448, filed Jan. 7, 2003, Muller, G. et al.
U.S. Appl. No. 60/436,975, filed Dec. 30, 2002, Muller, G. et al.
U.S. Appl. No. 60/366,515, filed Mar. 20, 2002, Muller, G. et al.
Akazome, M. et al., 1997, “Asymmetric recognition of 1-arylethylamines by (R)-phenylglycyl-(R)-phenylglycine and its mechanism,” Tetrahedron: Asymmetry, Elsevier Scince Publishers, Amsterdam, NL, 8(14):2331-2336.
Au et al., 1998,Brit. J. Pharm.123:1260-1266.
Baehr et al., 1979,J. Biol. Chem.254:11669.
Baughman et al., 1990,J. Lab. Clin. Med.115:36-42.
Beavo and Reifsnyder,Trends in Pharm., 11, 150-55, 1990.
Bissonnette et al., 1989,Inflammation13:329-339.
Bloom and Beavo 1996,Proc. Natl. Acad. Sci. USA93:14188-14192.
Brackeen, M.F. et al., 1995, “Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl) imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase”,J. Med. Chem.38:4848-54.
Carstensen, Jens T., 1995,Drug Stability: Principles&Practice, 2nd ed., Marcel Dekker, New York, NY pp. 379-380.
Casini et al., 1964, Farmaco Ed. Sci. 19:563.
Clouse et al., 1989,J. Immunol.142:431-438.
Derian et al., 1995, J. Immunol. 154:308-317.
Duh et al., 1989, Proc. Nat. Acad. Sci. 86:5974-5978.
Featherstone, R.L., et al., 2000, “Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs”, Am. J. Respir. Crit. Care Med. 162:850-6.
Gillespie et al., 1989,Mol. Pharm.36:773.
Hidaka and Asano 1976,Biochem. Biophys. Acta429:485.
Hinshaw et al. 1990.Circ. Shock30:2797-292.
Holler et al., 1990,Blood75:1011-1016.
Johnson et al., 1989,Endocrinology124:1424-1427.
List et al., 1990,J. Clin. Oncol.8:1424.MDS.
Luke, G.P. et al., 1999, “Synthesis of (S)-5-(1-aminoethyl)-2-(cyclohexylmethoxy) benzamide,” Tetrahedron: Asymmetry, Elsevier Science Publishers, Amsterdam, NL, 10(22):4393-4403.
Merck Manual (1999) 17thed., 953.
Monté et al., 1990,Blood79:2670.
Muller, George, et al., 1999,Bioorganic&Medicinal Chemistry Letters9; pp. 1625-1630.
Muller et al., 1998,Bioorg.&Med Chem Lett.8:2669-2674.
Muller, et al., 1996,J. Med. Chem.39:3238.
Nicholson et al., 1991,Trends Pharmaco. Sci.12:19.
Shealy et al., 1965, “D- and L-thalidomide.”Chem. Indus.12;24:1030-1.
Tierney, et al., ed., 1998, Current Medical Diagnosis & Treatment, 37thed., Appleton & Lange, pp. 499.
Verghese, et al.,Journal of Pharmacology and Experimental Therapeutics, 272(3), 1313-1320, 1995.
Van Dullemen et al., 1995,Gastroenterology, 109:129-135.
Wilen, S.H., et al., 1977,Tetrahedron33:2725.
Wilen, S.H., 1972,Tables of Resolvin

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3991424

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.